EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
January 31, 2023 13:46 ET | EnGeneIC
Protects against mutant strainsPromotes a long term memory responseNo side effects in healthy volunteersVaccine stored and transported at room temperature with long shelf lifeSeeking...
EnGeneIC’s second generation COVID-19 vaccine protects against all variants
June 28, 2022 07:00 ET | EnGeneIC
SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The world’s first COVID-19 vaccine to offer immunity against all variants is one step closer. Clinical trials have shown the novel vaccine works...
Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment
November 30, 2021 07:00 ET | EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both...
Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response
September 07, 2021 22:26 ET | EnGeneIC
Works against mutant strains including DeltaNo need for refrigeration during transport and storage No added stabilisers or chemicals Safety and immune response clinical trial recruiting now in...